The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Separating drug-induced from IBD-associated granulomatosis with polyangiitis can be extremely challenging (PMID 24525506)
Publications
Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease.
The American journal of surgical pathology 2014 Mar;38;354-9 — 2014 Mar — 354-9
Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.
Clinical nephrology 2009 Jan;71;74-9 — 2009 Jan — 74-9
Bilateral pulmonary infiltrates in a patient with ulcerative colitis receiving mesalazine.
European journal of internal medicine 2004 Nov;15;470-472 — 2004 Nov — 470-472
Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
Arthritis and rheumatism 2000 Feb;43;405-13 — 2000 Feb — 405-13
Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis.
Chest 1996 Aug;110;556-9 — 1996 Aug — 556-9